UPDATE: Novogen CEO Graham Kelly Resigns

The Board of Directors of Novogen Limited NVGN wishes to advise that it has accepted the resignation of its Chief Executive Officer and Director, Dr Graham Kelly, effective today. Dr Kelly has decided to leave the Company to resume his work in non-oncology based early stage research. During his time as Chairman of the Board and Chief Executive Officer, Dr Kelly has shown great commitment and energy in ensuring that Novogen is in a sound financial position with three drug candidates on track to enter Phase 1 clinical trials in 2016/17. Dr Kelly said, "I am satisfied that I am leaving the Company in a very sound position. The Company is well placed now to proceed into the clinic with its 3 oncology drug candidates. It doesn't require me to steer it from here. My particular interest and skills are in early-stage drug development, and I now want to focus on that." The Board wishes Dr Kelly well in his future endeavours. An announcement regarding the steps that Novogen will take to fill this role will be made in the near future.